Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl
NDC Package 69729-222-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl is temporarily relieves these symptoms of hay fever or other respiratory allergies:HeadacheNasal congestionSinus congestion & pressureRunny nose and sneezingMinor aches & painTemporarily relieves these additional symptoms of hay fever:itching of the nose or throatitchy, watery eyeshelps clear nasal passageshelps decongest sinus opening and passages. Marketed by Opmx Llc, this product is identified by NDC 69729-222 and is authorized under FDA application part341.

Identification & Billing

NDC Package Code
69729-222-06
Package Description
3 POUCH in 1 CARTON / 2 TABLET in 1 POUCH
Product Code
11-Digit Billing Format
69729022206
RxNorm Crosswalk
  • RxCUI: 2463332 - acetaminophen 500 MG / chlorpheniramine maleate 4 MG / phenylephrine HCl 10 MG Oral Tablet
  • RxCUI: 2463332 - acetaminophen 500 MG / chlorpheniramine maleate 4 MG / phenylephrine hydrochloride 10 MG Oral Tablet
  • RxCUI: 2463332 - APAP 500 MG / chlorpheniramine maleate 4 MG / phenylephrine hydrochloride 10 MG Oral Tablet

Clinical Specifications

Proprietary Name
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl
Dosage Form
-
Usage Information
Temporarily relieves these symptoms of hay fever or other respiratory allergies:HeadacheNasal congestionSinus congestion & pressureRunny nose and sneezingMinor aches & painTemporarily relieves these additional symptoms of hay fever:itching of the nose or throatitchy, watery eyeshelps clear nasal passageshelps decongest sinus opening and passages

Regulatory & Marketing

Labeler Name
Opmx Llc
FDA Application #
part341
Marketing Category
OTC MONOGRAPH FINAL - A product marketed pursuant to a final Over-the-Counter (OTC) Drug Monograph.
Start Marketing Date
08-26-2019
Listing Expiration
12-31-2024
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (69729-222). Click a package code to view its specific billing and regulatory data.

2 TABLET in 1 POUCH
12 TABLET in 1 POUCH
144 TABLET in 1 POUCH

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69729-222-06 identifies a specific commercial package of 3 pouch in 1 carton / 2 tablet in 1 pouch of Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl, labeled by Opmx Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Opmx Llc on August 26, 2019. The current certification is valid through December 31, 2024.

How is this Opmx Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69729022206. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69729-222-06
11-Digit CMS (5-4-2)
69729-0222-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.